



DIAGNÓSTICOS DA AMÉRICA S.A.

Publicly-held Company

CNPJ/ME 61.486.650/0001-83

NIRE 35.300.172.507

NOTICE TO THE MARKET

DIAGNÓSTICOS DA AMÉRICA S.A., a corporation headquartered in the city of Barueri, state of São Paulo, at Avenida Juruá, nº 434, Alphaville, CEP 06455-010, enrolled with the National Registry of Legal Entities of the Ministry of Economy ("CNPJ/ME") No. 61.486.650/0001-83 ("the Company", or "Dasa"), informs its shareholders and the market in general, in continuation of notice released on April 1, 2022, the conclusion on this date of **ÍMPAR SERVIÇOS HOSPITALARES S.A.** ("Ímpar"), Dasa's wholly-owned subsidiary's acquisition of ninety percent (90%) of the quotas representing the capital stock of **CENTRON – CENTRO DE TRATAMENTO ONCOLÓGICO LTDA.** ("Centron"), a company operating in the city of Rio de Janeiro, which provides chemotherapy and healthcare services in the hematology, oncology, and related specialties areas, including bone-marrow transplants ("Transaction").

The Centron clinic is headed by Dr. Daniel Tabak, a reference in oncology and onco-hematology in the South area of the city of Rio de Janeiro, it relies on eighteen (18) infusion seats and ten (10) doctor's offices, totaling gross operating revenue (GOR) of thirty million Reais (R\$30,000,000.00) in 2021.

The Company underlines that this Transaction is in line with its expansion plans, it also reiterates its commitment to keep shareholders and the market, in general, informed of the progress of the Transaction and any other issue of market interest.

Barueri/SP, May 13, 2022.

Andrew Thomas Campbell

Investor Relations Officer